3D MoA on AAV Gene Therapy for XLRS

Atsena Therapeutics requested a MoA animation to support investor relations and broader stakeholder communication. Our scientific team first reviewed the underlying biology and therapeutic approach before developing initial animation scripts. Following internal development, we collaborated with Atsena to refine the narrative, incorporating their feedback before moving into production. The process followed a structured pipeline—from storyboards to animatics to final renders—managed independently by Visual Science, while maintaining regular review points that allowed the client to guide direction without requiring constant involvement.

To clearly communicate both the disease mechanism of XLRS and Atsena’s gene therapy approach, we developed a hybrid visual system combining 3D retinal environments, molecular animation, 2D graphical overlays, and live-action footage. The retinal environment illustrates schisis cavity formation, while molecular models highlight the role of retinoschisin and the impact of RS1 mutations. The therapeutic sequence focuses on clarity of delivery, showing subretinal injection, localized bleb formation, and lateral spread of the AAV capsid across the retina, connecting gene delivery to restored protein expression and visually representing retinal repair within a consistent visual language.